BSE: 524518 | NSE: KREBSBIO | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Krebs Biochemicals & Industries Ltd is a below average quality company.
The key valuation ratios of Krebs Biochemicals & Industries Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Krebs Biochemicals & Industries Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.3% | -25.4% | -27.1% | -29% | -35.4% | -57% | -40.3% | -57.4% | -28.6% | -19% | - |
| Value Creation Index ⓘ | NA | -2.8 | -2.9 | NA | NA | NA | NA | NA | NA | NA | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 1.3 | 3.5 | 33.8 | 47.8 | 33.4 | 53.7 | 59.7 | 52.1 | 50.4 | 51 |
| Sales YoY Gr. | - | NA | 173.6% | 856.9% | 41.4% | -30.1% | 60.7% | 11.2% | -12.7% | -3.3% | - |
| Adj EPS ⓘ | -20.1 | -12.9 | -11.4 | -12.4 | -12.1 | -16 | -14.5 | -20.7 | -11.5 | -9.2 | -10.1 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | -9.3 | 6.9 | 1 | -12.5 | -8.6 | -18.1 | -23.9 | -34.8 | -46.1 | -55.3 | -60.4 |
| Adj Net Profit ⓘ | -19.8 | -17.4 | -16.2 | -17.6 | -20.1 | -28.9 | -28.4 | -44.5 | -24.7 | -19.7 | -22 |
| Cash Flow from Ops. ⓘ | -90.5 | -15.3 | -11.2 | -6.2 | 3.9 | -35.5 | -14.6 | -17.2 | -24.7 | 2.3 | - |
| Debt/CF from Ops. ⓘ | -1.4 | -2 | -4.2 | -9.1 | 13.7 | -1.9 | -7.6 | -8.3 | -7.4 | 84.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 1.1% | -2.1% | -3.3% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | NA | NA | NA | NA | ||||
| Share Price | 11.4% | 4.2% | -14.3% | 28.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -90.6 | -111.2 | -224.2 | 216.4 | 125.3 | 147 | 83.7 | 75.6 | 28.3 | 18 | 17.5 |
| Op. Profit Mgn % ⓘ | 0 | -961.7 | -226.6 | -22.2 | -20.4 | -55.5 | -32.7 | -56.9 | -30.3 | -17.3 | -19.9 |
| Net Profit Mgn % ⓘ | 0 | -1349.5 | -460.1 | -52.2 | -42.1 | -86.4 | -52.8 | -74.6 | -47.4 | -39.1 | -42.9 |
| Debt to Equity ⓘ | -13.3 | 3.3 | 32.2 | -3.2 | -3.7 | -2 | -2.4 | -1.9 | -1.8 | -1.6 | - |
| Working Cap Days ⓘ | 0 | 7,106 | 1,488 | 201 | 158 | 243 | 179 | 218 | 231 | 179 | 79 |
| Cash Conv. Cycle ⓘ | 0 | 1,149 | 366 | -17 | -32 | -1 | 1 | 21 | 0 | -11 | -219 |
Sales growth is good in last 4 quarters at 13.86%
Return on Equity has declined versus last 3 years average to 17.40%
Sales growth has been subdued in last 3 years -2.08%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -10.1 | - |
| TTM Sales (₹ Cr.) | 50.7 | - |
| BVPS (₹.) ⓘ | -60.4 | - |
| Reserves (₹ Cr.) ⓘ | -152 | - |
| P/BV ⓘ | -1.69 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 60.00 / 129.00 |
| All Time Low / High (₹) | 9.10 / 293.59 |
| Market Cap (₹ Cr.) | 220 |
| Equity (₹ Cr.) | 21.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 4 | 34 | 48 | 33 | 54 | 60 | 52 | 50 |
| Operating Expenses ⓘ | 5 | 14 | 12 | 41 | 58 | 52 | 71 | 94 | 68 | 59 |
| Manufacturing Costs | 1 | 4 | 2 | 13 | 16 | 17 | 26 | 33 | 23 | 33 |
| Material Costs | 0 | 0 | 1 | 13 | 23 | 16 | 26 | 41 | 26 | 7 |
| Employee Cost | 2 | 6 | 6 | 11 | 14 | 15 | 15 | 15 | 16 | 16 |
| Other Costs ⓘ | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 3 | 3 |
| Operating Profit ⓘ | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 |
| Operating Profit Margin (%) | - | -961.0% | -226.0% | -22.2% | -20.4% | -55.5% | -32.7% | -56.9% | -30.3% | -17.3% |
| Other Income ⓘ | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Interest ⓘ | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 |
| Depreciation ⓘ | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 |
| Exceptional Items ⓘ | 3 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 |
| PAT Margin (%) | - | -1,265.5% | -454.0% | -52.8% | -41.9% | -86.4% | -52.8% | -74.6% | -47.4% | -39.1% |
| Adjusted EPS (₹) | -8.0 | -12.1 | -11.3 | -12.5 | -12.0 | -16.0 | -14.5 | -20.7 | -11.5 | -9.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | -5 | 9 | 1 | -18 | -14 | -33 | -47 | -75 | -99 | -119 |
| Share Capital ⓘ | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 |
| Reserves ⓘ | -14 | -4 | -12 | -32 | -31 | -51 | -67 | -97 | -121 | -141 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 58 | 25 | 43 | 52 | 50 | 66 | 111 | 143 | 183 | 193 |
| Long Term Debt | 58 | 25 | 43 | 52 | 50 | 66 | 101 | 133 | 173 | 184 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 | 10 | 10 |
| Trade Payables | 17 | 12 | 11 | 18 | 21 | 23 | 21 | 38 | 15 | 19 |
| Others Liabilities ⓘ | 38 | 69 | 67 | 74 | 85 | 78 | 75 | 84 | 76 | 85 |
| Total Liabilities ⓘ | 107 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 |
Fixed Assets | ||||||||||
| Gross Block | 167 | 213 | 227 | 230 | 234 | 243 | 261 | 288 | 303 | 312 |
| Accumulated Depreciation | 116 | 120 | 124 | 129 | 133 | 138 | 143 | 149 | 156 | 163 |
| Net Fixed Assetsⓘ | 51 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 |
| CWIP ⓘ | 7 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 5 | 6 | 5 | 12 | 9 | 15 | 17 | 26 | 12 | 10 |
| Trade Receivables | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 1 | 1 | 2 |
| Cash Equivalents | 6 | 0 | 0 | 0 | 17 | 0 | 1 | 0 | 0 | 0 |
| Others Assetsⓘ | 37 | 7 | 9 | 9 | 8 | 9 | 12 | 16 | 11 | 14 |
| Total Assets ⓘ | 107 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -45 | -15 | -11 | -6 | 4 | -35 | -15 | -17 | -25 | 2 |
| PBT ⓘ | -11 | -17 | -16 | -17 | -20 | -29 | -28 | -45 | -25 | -20 |
| Adjustment ⓘ | 9 | 3 | 11 | 6 | 10 | 9 | 12 | 11 | 10 | 12 |
| Changes in Working Capital ⓘ | -39 | -1 | -2 | 9 | 14 | -16 | 2 | 16 | -10 | 10 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 |
| Capex | -3 | 4 | -13 | -4 | -5 | -9 | -18 | -27 | -15 | -9 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | -8 | 9 | 2 | 1 | -2 | -5 | 4 | 3 | 2 |
| Cash Flow From Financing Activityⓘ | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 |
| Net Proceeds from Shares ⓘ | 19 | 19 | 4 | 0 | 25 | 19 | 10 | 13 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 35 | 8 | 17 | 9 | -2 | 15 | 33 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | -6 | -6 | -6 | -5 | -3 | -5 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | -14 | -5 | 0 | 1 | 0 | 0 | 32 | 40 | 10 |
| Net Cash Flow ⓘ | 6 | -6 | 0 | 0 | 17 | -17 | 1 | -1 | 0 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | -683.34 | -296.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| ROCE (%) | N/A | -25.38 | -27.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover Ratio | 0 | 0.01 | 0.03 | 0.27 | 0.36 | 0.24 | 0.37 | 0.34 | 0.29 | 0.29 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Working Capital Days |
| Receivable Days | 0 | 52 | 84 | 10 | 12 | 17 | 2 | 4 | 5 | 9 |
| Inventory Days | 0 | 1,436 | 573 | 93 | 79 | 131 | 107 | 129 | 131 | 79 |
| Payable Days | 0 | 0 | 3,559 | 414 | 310 | 507 | 305 | 264 | 378 | 949 |
Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.
KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.
KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.
The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.
KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).
Product range of the company includes:
Bulk activities
Synthetic Lavastatin
Herbal
Intermediates
Products in pipeline
Achievements/ recognition:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
